data

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data…

4 months ago

Dun & Bradstreet Honours Public Sector Excellence at the PSU & Government Summit 2025

MUMBAI, India, Oct. 23, 2025 /PRNewswire/ -- Dun & Bradstreet, a leading global provider of business decisioning data and analytics,…

4 months ago

Alps Blockchain Announces Corporate Rebranding to Alps

Reflecting its evolution into a global builder of next-generation data center infrastructure powering Bitcoin and, in the future, AI computation TRENTO,…

4 months ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered…

4 months ago

Inveniam and MANTRA Unveil Inveniam Chain: A Layer 2 Blockchain for the Management and Utilization of Private Real Estate Assets

ABU DHABI, UAE and DUBAI, UAE and NEW YORK, Oct. 21, 2025 /PRNewswire/ -- Inveniam Capital Partners ("Inveniam"), a global leader in decentralized…

4 months ago

IIFL Finance Engages Leegality's Consentin for DPDP Compliance

IIFL Finance, one of India’s leading financial institutions, has engaged with Consentin by Leegality, a Digital Personal Data Protection (DPDP)…

4 months ago

Benchling Partners with Anthropic to Build a Bridge Between Science and AI

Claude's Life Sciences Ecosystem pairs Benchling AI with advanced reasoning in Claude SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- Benchling…

4 months ago

Dun & Bradstreet Showcases India’s Strategic Edge at the GCC Summit 2025

MUMBAI, India, Oct. 16, 2025 /PRNewswire/ -- Dun & Bradstreet, a leading global provider of business decisioning data and analytics,…

4 months ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

4 months ago

PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…

4 months ago